Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK India Managing Director Hasit Joshipura: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Joshipura discusses what lies ahead for India’s largest multinational drug company.

You may also be interested in...

GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 1 of 2)

GlaxoSmithKline India Managing Director Hasit Joshipura is known as one of the most aggressive multinational pharma directors in India in terms of expansion strategy. Some top GSK officials say he was brought in at the helm with the task of making GSK sharper in its marketing approach. Joshipura presented those capabilities in his earlier stint as the managing director at Johnson & Johnson India. Joshipura sat down with PharmAsia News' India bureau to discuss what lies ahead for India's largest multinational drug company.

GSK “Delighted” By India’s Supreme Court Ruling In 10-Year Exclusive Marketing Rights Battle Over Avandia

MUMBAI - The Supreme Court of India has upheld a Calcutta High Court decision to grant exclusive marketing rights to GlaxoSmithKline's anti-diabetes drug Avandia in a landmark judgment that will have wide repercussions on product patent applications by multinational companies in India

GSK To Take Second Shot At The Rural Indian Market; Considering Customized Strategy

MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts